66735-04-4

Usage

InChI:InChI=1/C14H20O2/c1-10(13(15)16)9-11-5-7-12(8-6-11)14(2,3)4/h5-8,10H,9H2,1-4H3,(H,15,16)

Upstream product

• 545393-77-9 (E)-3-(4-(tert-butyl)phenyl)-2-methylacrylic acid 
• 910534-85-9 2-(4-t-butyl-benzyl)-2-methyl-malonic acid dimethyl ester 
• 54017-13-9 ethyl 2-hydroxy-3-(4-tert-butylphenyl)-3-butenoate 
• 80-54-6 lilial 
• 27798-45-4 1-allyl-4-(tert-butyl)benzene 

Downstream Products

• 910534-86-0 3-(4-t-butyl-phenyl)-N-(4-methanesulfonylamino-benzyl)-2-methyl-propionamide 

Relevant academic research and scientific papers

Carbonylative Transformation of Allylarenes with CO Surrogates: Tunable Synthesis of 4-Arylbutanoic Acids, 2-Arylbutanoic Acids, and 4-Arylbutanals

In this Communication, procedures for the selective synthesis of 4-arylbutanoic acids, 2-arylbutanoic acids, and 4-arylbutanals from the same allylbenzenes have been developed. With formic acid or TFBen as the CO surrogate, reactions proceed selectively and effectively under carbon monoxide gas-free conditions.

SILICON-BASED FUNGICIDES AND PROCESS FOR PRODUCING THE SAME

The present invention discloses novel antifungal compounds of formula (I), method for preparing these compounds and the use of these compounds as antifungal agents in prevention and treatment of fungal infections, and compositions containing these novel c

Oxidative degradation of fragrant aldehydes. Autoxidation by molecular oxygen

The oxidative degradation of fragrant aldehydes by molecular oxygen has been investigated. The oxygen consumption was monitored and the bond dissociation energy (BDE) of the aldehyde C(O)-H bond were calculated by DFT method. The oxidation products were identified by GC/MS. The different pathways accounting for the oxidative degradation are discussed. The main product is the acid, beside the formate ester. Both oxidation products result from the Baeyer-Villiger reaction involving a peracid R(CO)OOH whereas minor products arise from the hydroperoxide ROOH intermediate derived either from the acyl peroxy radical, R(CO)OO or from the decarboxylation of the peracid RC(O)OOH.

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The present invention

2-Hydroxy-3(4-alkylphenyl)-3-butenoic acid ester and process for the production thereof

A new process for the production of a 2-(4-alkylphenyl)-propionic acid known as a valuable anti-inflammatory agent is now provided, which comprises treating an alkyl 2-hydroxy-3-(4-alkylphenyl)-3-butenoate, a new compound, with an alkali metal alcoholate in an alcohol to give the corresponding alkyl 3-methyl-3-(4-alkylphenyl)-pyruvate, also a new compound, which is then hydrolysed to liberate the corresponding 3-methyl-3-(4-alkylphenyl)-pyruvic acid, and then oxidising the liberated pyruvic acid compound to the desired 2-(4-alkylphenyl)-propionic acid. This new process is operable in a facile way with a high yield of the desired product and is much suitable for a commercial practice than the prior art methods.